Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) has announced that its controlled subsidiary, Shanghai Henlius Biotech, Inc., along with its own controlled subsidiaries (collectively referred to as "Henlius"), recently received approval from the National Medical Products Administration. The approval grants permission to conduct a Phase I clinical trial of HLX316 for injection, a targeted B7-H3 sialidase Fc fusion protein, for the treatment of advanced/metastatic solid tumors. Henlius plans to initiate the related clinical research in China once conditions are met. HLX316 is a novel, first-in-class, targeted B7-H3 sialidase heterodimer developed by the group through the fusion of a B7-H3-targeting heavy-chain-only antibody variable domain (VHH) with a licensed sialidase bifunctional fusion protein. It is intended for the treatment of advanced/metastatic solid tumors.